文献速递脑血管病

脑出血后三联降压药物预测评分(TRICH评分)

Triple Antihypertensive Medication Prediction Score After Intracerebral Hemorrhage (the TRICH Score).
PubMed 文献 · Neurology · 2025-04-04

研究基于香港大学前瞻性ICH登记(2011-2022)开发TRICH评分,并在3家医院(2020-2022)验证,用于预测ICH后3个月需要≥3种降压药的患者。评分9分,开发队列c-statistic 0.79(95%CI 0.75-0.83),验证队列0.76(95%CI 0.69-0.82);≥3分预测需要≥3种降压药的敏感度0.73(95%CI 0.67-0.80),特异度0.76(95%CI 0.70-0.81)。

要点

  • TRICH评分用于预测ICH后3个月需要≥3种降压药,9分制,c-statistic开发队列0.79、验证队列0.76。
  • 评分≥3分预测需要≥3种降压药的敏感度0.73(95%CI 0.67-0.80),特异度0.76(95%CI 0.70-0.81)。
  • 评分在ICH前未治疗/未控制高血压患者中表现更好(c-statistic 0.81 vs 0.74,p=0.037),CAA与非CAA患者间无差异。

核心结论

  • TRICH评分能较好区分ICH后3个月需要≥3种降压药的患者,可能指导 upfront 三联降压处方,但需进一步研究,尤其在非汉族人群。

研究设计与样本

  • 研究基于香港大学前瞻性ICH登记(2011-2022)开发评分,并在当地3家医院(2020-2022)验证。
  • 纳入连续的自发性ICH患者,要求存活>90天且ICH后3个月有随访血压。
  • 开发队列462例(平均年龄66.6±14.3岁,60%男性),验证队列203例(平均年龄66.3±14.6岁,62%男性)。
  • 采用多变量logistic回归识别预测因子,并基于β系数构建评分。

主要发现

  • TRICH评分为9分制:年龄<60岁=1分,男性=1分,缺血性心脏病=1分,入院eGFR<60 mL/min/1.73 m2=2分,入院收缩压190-230 mm Hg=2分,>230 mm Hg=4分。
  • 开发队列c-statistic(95%CI)为0.79(0.75-0.83),验证队列为0.76(0.69-0.82)。
  • 二分类评分(≥3分)预测需要≥3种降压药的敏感度为0.73(95%CI 0.67-0.80),特异度为0.76(95%CI 0.70-0.81)。
  • 评分在ICH前未治疗/未控制高血压患者中优于已控制患者(c-statistic [95%CI] 0.81 [0.77-0.86] vs 0.74 [0.69-0.80],p=0.037)。
  • 评分在CAA与非CAA患者间无差异。

关键数值与推荐

  • TRICH评分≥3分预测ICH后3个月需要≥3种降压药,敏感度0.73(95%CI 0.67-0.80),特异度0.76(95%CI 0.70-0.81)。
  • 评分在未治疗/未控制高血压患者中c-statistic为0.81(95%CI 0.77-0.86),在已控制患者中为0.74(95%CI 0.69-0.80),p=0.037。

临床怎么用

  • TRICH评分可能指导ICH后 upfront 三联降压处方,但需进一步研究,尤其在非汉族人群。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Poor long-term blood pressure (BP) control due to undertreatment of hypertension is not uncommon after intracerebral hemorrhage (ICH). It heightens the risk of ICH recurrence and subsequent stroke, which is the highest within the first year. Promptly achieving BP targets would significantly reduce these risks. To accomplish this, upfront triple antihypertensive medications could be prescribed soon after ICH because many ICH survivors require ≥3 antihypertensives. However, not all would suit this approach, particularly those with cerebral amyloid angiopathy (CAA), where elevated admission BP may be due to acute hypertensive response rather than underlying hypertension. In addition, overtreatment and excessive BP lowering would cause more side effects and have been associated with increased mortality in older patients. Hence, to facilitate individualized treatment, we aimed to develop a score (TRICH) to predict the need for ≥3 antihypertensives at 3 months after ICH. METHODS: We developed the score using data from the University of Hong Kong prospective ICH registry (2011-2022) and validated it in 3 hospitals (2020-2022) locally. Consecutive patients with spontaneous ICH who survived >90 days and had follow-up BP 3 months after ICH were included. Predictors for needing ≥3 antihypertensive medications at 3 months were identified using multivariate logistic regression, and the score was created using the β-coefficients. RESULTS: The TRICH score was developed from 462 patients (mean age 66.6 ± 14.3 years, 60% male) and validated in 203 patients (mean age 66.3 ± 14.6 years, 62% male). The 9-point score (age younger than 60 years = 1, male = 1, ischemic heart disease = 1, admission estimated glomerular filtration rate <60 mL/min/1.73 m2 = 2, admission systolic BP 190-230 mm Hg = 2 while >230 mm Hg = 4) has a c-statistic (95% CI) of 0.79 (0.75-0.83) in the development cohort and 0.76 (0.69-0.82) in validation. A dichotomized score (≥3 points) predicted the need for ≥3 antihypertensives with 0.73 (95% CI 0.67-0.80) sensitivity and 0.76 (95% CI 0.70-0.81) specificity. The score performed better in patients with untreated/uncontrolled hypertension before ICH than in controlled patients (c-statistic [95% CI] 0.81 [0.77-0.86] vs 0.74 [0.69-0.80], p = 0.037) but showed no difference between patients with CAA and non-CAA patients. DISCUSSION: The TRICH score identifies patients with ICH who need ≥3 antihypertensive medications 3 months after ICH with good discrimination ability. It may guide upfront triple antihypertensive prescription, but further research is warranted, particularly in non-Han Chinese populations.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. So CH, Yeung C, Ho RW, et al. Triple Antihypertensive Medication Prediction Score After Intracerebral Hemorrhage (the TRICH Score). Neurology. 2025. PMID: 40184593. doi:10.1212/WNL.0000000000213560

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。